Searched for
PHARMA INDEX
India likely past peak outflows, AI gap its advantage, Lighthouse Canton saysDomestic benchmarks Nifty 50 and Sensex are down about 11% and 13% so far in 2026, respectively, after fears of AI-led disruption tanked th...- Two Trades for Today: 2 pharma companies – a large-cap for a 5% rise, and a mid-cap stock for a gain of 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...
- 'Time to cherry pick again': Porinju Veliyath says small and midcaps have bottomed & Thomas Cook is his latest buyPorinju Veliyath sees the correction in small and midcap stocks ending. He believes patient investors will find rewards. Thomas Cook India ...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- How Sensex, Nifty rallied 200% under PM Modi's record-breaking tenureIndian equity markets delivered strong long-term returns during Prime Minister Narendra Modi’s tenure, with the Sensex and Nifty gaining ar...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- Sensex down over 10K points from Dec peak. Should MF investors buy the dip, hold positions, or wait on sidelines?The BSE Sensex has fallen over 10,000 points from its peak. Market experts suggest this presents a buying opportunity for long-term investo...
- 100 days of Iran war, Rs 4,50,000 crore wiped out: Is your stock portfolio safe from missiles?Indian equities have lost Rs 4.5 lakh crore in 100 days as the Iran-led West Asia conflict and a global AI trade unwind trigger sharp FII o...
- Dalal Street Week Ahead: Will Nifty hold 23,000 as markets test key support?The markets ended lower this week, with Nifty trading below its 50 and 100-week moving averages. While a crucial support zone near 23,000-2...
- Full impact of inflation not yet in earnings; may reflect next quarter, warns Unmesh SharmaHDFC Securities' Unmesh Sharma anticipates the full impact of inflation on corporate earnings will surface in the June quarter, potentially...
- Market correction nearing its end; bet on banking, pharma: Rohit SrivastavaMarket correction may be nearing its end, with Nifty approaching a key support zone around 23,077. Banking, energy, and metals sectors show...
- AI talent demand offset flat white-collar hiring in MayIndia's job market showed stability in May. Insurance sector hiring grew significantly. Demand for AI talent remained strong, especially fo...
- Ahead of Market: 10 things that will decide stock market action on TuesdayBenchmark indices Sensex and Nifty fell for a fourth straight session amid elevated crude oil prices, geopolitical tensions and persistent ...
- Pankaj Pandey identifies defence, pharma and consumption as core stock picking themesIndian equities face a mixed outlook due to potential monsoon deficit and uneven corporate earnings. While rural-linked sectors may see pre...
- Bearish move or buying opportunity? Geojit's Anand James on Nifty levels and top stocks to watchMarket volatility surged following a late-Friday sell-off, with MSCI rebalancing and global cues cited as triggers. Geojit Financial Servic...
- Ahead of Market: 10 things that will decide stock market action on MondayIndian equity markets ended sharply lower on May 29 amid broad-based selling, MSCI-driven flows and rising volatility. Technical indicators...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Dalal Street Week Ahead: Nifty stuck in consolidation zone; 23,800 remains key breakout hurdleMarkets experienced volatility and ended the week with a modest loss, primarily due to MSCI rebalancing flows. Nifty consolidated within a ...
- Nifty IT bottoming out? Anand James on the expiry outlook, pharma profit-booking, and 2 stocks to buy this weekGeojit Investments’ Anand James expects Nifty to attempt a range breakout above 23,700 during the monthly expiry week. He highlighted early...
Load More
